|
 |
|
|
|
|
Subscribe to Clinical Compass™ |
VOLUME 3, ISSUE 12 - JUNE 3, 2008 |
|
 |
|
|
|
|
|
|
|
LIVE CME/CE |
 |
|
Multidisciplinary CE Credits Offered!
|
|
View our full CME calendar online!
|
|
|
Augmenting Antidepressants with Atypical Antipsychotics in Major Depressive Disorder
Satellite Television Broadcast, Webcast, Telephone Simulcast
Premiere Date:
Wednesday, June 11, 2008
MODERATOR
Charles B. Nemeroff, MD, PhD |
FACULTY
Andrew A. Nierenberg, MD |
Mark Hyman Rapaport, MD |
Register Now! 
1st Annual Chairs in Psychiatry Summit - The Master Class for Psychiatric Professional Development
Date: June 27 - 29, 2008
Location:
The Westin Hilton Head Island
2 Grasslawn Avenue
Hilton Head Island, SC 29928
843.681.4000
CHAIRED BY:
Charles B. Nemeroff, MD, PhD |
Register Now!
|
|
SELF-STUDY CME/CE |
|
|
Multidisciplinary CE Credits Offered!
|
|
View our full library of complimentary self-study CE materials!
|
|
|
Addressing Clinical Challenges in the Long-Term Treatment of Schizophrenia
Podcast
Released: Friday, February 22, 2008
FACULTY
Charles B. Nemeroff, MD, PhD
Peter F. Buckley, MD
Stephen R. Marder, MD
John W. Newcomer, MD
Participate
Combating the Consequences of Excessive Sleepiness
Archived Videoconference
Released December 5, 2007
FACULTY
Charles B. Nemeroff, MD, PhD
David F. Dinges, PhD
Thomas Roth, PhD
Participate Order Online
Waking Up to the Problem of OSA: Consequences and Improved Recognition
Archived Audioconference
Released October 16, 2007
FACULTY
Sonia Ancoli-Israel, PhD
Barbara A. Phillips, MD, MSPH, FCCP
Participate Order Online
|
|
|
|
|
|
 |
|
|
FROM THE CLINICAL KNOWLEDGE CENTER:
Hepatitis C and Depression 
THIS ISSUE'S COMPASS QUESTIONS™
NEW neuroscienceCME TV PREMIERES NEXT WEEK!
AN INVITATION FROM DR. NEMEROFF
|
 |
|
|
FROM THE CLINICAL KNOWLEDGE CENTER
Hepatitis C and Depression
In the United States there are an estimated 4.1 million people infected with hepatitis C virus (HCV). While 15% to 25% of people newly infected will clear the virus spontaneously, the majority will need pharmacologic intervention. Currently the FDA-approved forms of treatment are interferons alfa-2a or -2b (IFN alfa-2a or -2b), which may be covalently bound to polyethylene glycol (peg-IFN alfa), and are typically combined with ribavirin (RBV). Approximately one-third of people receiving therapy will experience treatment-induced depression, which can lead to the need for dose decreases or medication discontinuation. Iatrogenic depression is related to type of treatment, dose, duration, and route of administration. For instance, the addition of RBV may increase/induce depression, with one investigation finding that depression ratings followed a dose-response relationship...
Read entire article
Back to top 
|
|
|
|
NEW neuroscienceCME TV
PREMIERES NEXT WEEK!
Augmenting Antidepressants with Atypical Antipsychotics in Major Depressive Disorder
Premiere Date: Wednesday, June 11, 2008
Live Broadcast: 12:00-1:00 p.m. ET
Taped Re-Air: 3:00-4:00 p.m. ET
ACTIVITY GOAL
To describe the neurobiology of depression as it relates to mechanisms of drug action, and discuss augmentation strategies with atypical antipsychotics for the substantial group of patients who do not remit with traditional antidepressants.
LEARNING OBJECTIVES
At the end of this CE activity, participants should be able to:
- Identify remission rates among patients treated for major depressive disorder and strategies to improve remission rates in depression.
- Explain the neurobiology of depression and the mechanisms by which traditional antidepressants and atypical antipsychotic medications exert their effects.
- Compare and contrast the efficacy and safety of atypical antipsychotics when used as augmentation to traditional antidepressants in the management of depression.
CREDIT INFORMATION
This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
Back to top
|
|
AN INVITATION FROM DR. NEMEROFF
Charles B. Nemeroff, MD, PhD, is the chair of psychiatry and behavioral sciences at the Emory University School of Medicine in Atlanta. He is also the Summit Chair for the 1st Annual Chairs in Psychiatry Summit-The Master Class for Psychiatric Professional Development. As Summit Chair, Dr. Nemeroff will lead a group of over 2 dozen psychiatry department chairs from across the country as they convene in Hilton Head, SC, in late June. Together these influential experts in the neurosciences will serve as faculty presenters for the inaugural Chair Summit. This extraordinary educational event is open to all mental health professionals but only 400 spots are available and are filling fast.
Please click here to listen to Dr. Nemeroff's personal invitation! We hope you'll consider joining him and his colleagues for this unique learning opportunity. For additional registration, lodging, and credit details, visit www.neuroscienceCME.com/CC303 or call the CME Outfitters Registrar Department at 877.263.7767.
Back to top
|
|
|
|
|
|
|
|
|
|
Problems receiving e-mail from us? Add webmaster@cmeoutfitters.com to your address book.
CME Outfitters, LLC, reserves the right to cancel any activity or make necessary changes in dates, times, speakers, content, and other details without notice. CME Outfitters, LLC, and the commercial supporters of these activities are not responsible for any speaker's or registrant's statements, materials, acts, or omissions.
|
|
|
|
|
©2008 CME Outfitters, LLC
|
|
|
|
